The company's breakthrough potential comes not from collecting raw DNA, but from linking it at an individual level to a rich set of "phenotype" data, including proteomics, metabolomics, and transcriptomics. This deep, multi-layered dataset from novel populations is what unlocks actionable insights for drug discovery.

Acknowledging the "garbage in, garbage out" principle, Haya heavily invests in generating high-quality, layered, and paired multi-omic data from the same biological material. This curated input is considered the most critical component for building effective AI models to unlock new biology.

The controversy and business opportunity in polygenic embryo selection lie in interpreting genetic data, not in the physical sequencing. Companies are competing on the quality and scope of their predictive models for health and traits, which they apply to data from established lab processes.

Unlike traditional biotechs focused on drug assets, Lila's primary product is its core scientific reasoning AI model. The advanced automated lab exists solely as a 'token generator'—a data-creation engine whose output serves as the competitive moat by continuously making the model smarter.

The next inflection point will come from clever data generation strategies optimized for AI models, not human analysis. This "black box data" approach—like pooled screening with sequencing readouts—is vastly more scalable and creates a powerful, proprietary moat for companies.

For NGS service providers, the core value is not the sequencing machine itself, as they are technology-agnostic. The real intellectual property and differentiation lie in the proprietary sample preparation techniques before sequencing and the bioinformatic data analysis pipeline and databases used afterward.

InduPro's AI advantage isn't a better algorithm but a superior, proprietary dataset generated in-house. This high-quality data, combining proximity maps with protein quantification, is the true differentiator that their tailor-made AI tools interrogate, avoiding reliance on public data.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

While public AI models are powerful, they risk becoming commodities when trained on the same public data. Regeneron's strategy is to create a durable advantage by training AI models on its unique dataset of millions of genomes, proteomes, and linked health records to deeply understand human biology.